Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain - Endpoints News

Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain    Endpoints News Biogen's Aduhel... thumbnail 1 summary
  1. Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain  Endpoints News
  2. Biogen's Aduhelm sales fall dramatically below Wall Street's expectations  STAT
  3. Biogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.  Barron's
  4. Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3  MarketWatch
  5. View Full Coverage on Google News


from Top stories - Google News https://ift.tt/3lVxnFw

No comments

Post a Comment

Subscribe to: Post Comments (Atom)